investing

Vanguard Health Care Hit Hard by Politics

This Kiplinger 25 fund is looking to get back on track with firms that push innovation.

Even great funds stumble occasionally. Case in point: Vanguard Health Care (VGHCX), which has delivered the highest return of any stock mutual fund over the past 30 years. After seven straight years of gains, Health Care lost 9% in 2016. And though its one-year return is now in the black, the fund trailed Standard & Poor’s 500-stock index by a decidedly unhealthy 17 percentage points over the past 12 months.

Problems for the fund, a member of the Kiplinger 25, stem mainly from troubles in its sector. Because health care makes up 18% of the U.S. economy, the sector often comes under fire during presidential election years, says the fund’s manager, Jean Hynes. In some election years, health care stocks take a hit before the vote; in others, it’s after. This time, “it was before and after,” she says.

Weighing most heavily on the sector were frequent denunciations of the high cost of pharmaceuticals and concerns that Congress might force drugmakers to roll back their prices. With 60% of Health Care’s assets invested in the catchall group that Hynes calls biopharmaceuticals, it’s no wonder her fund faltered. Changes to the Affordable Care Act loom, too, but Hynes says the structure of any new system would most likely be similar to what’s in place now and that any potential shifts would affect only 5% to 10% of the fund’s assets.

Hynes, who tilts toward large, undervalued firms with good long-term growth prospects, had her share of winners. UnitedHealth Group, a managed-care company and the fund’s top holding, returned 43% over the past year, buoyed by Optum, UnitedHealth’s fast-growing business that offers a broad array of health care serv­ices. And Incyte, a biotech firm that is developing drugs that target a body’s immune system to fight cancer, soared 72%.

Incyte is a good example of the kind of company Hynes favors. She is focusing on investing in established firms that have swiftly adapted or new ones that are pioneers—companies that are “ahead of the curve in terms of innovation,” she says, and that have rich pipelines of new drugs. One such company is Biogen, which recently won regulatory approval for the first drug to treat spinal muscular atrophy, a rare and often fatal genetic muscle disease.

Most Popular

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your second stimulus check.
January 18, 2021
When Could We Get a Third Stimulus Check?
Coronavirus and Your Money

When Could We Get a Third Stimulus Check?

President Biden and others in Congress are pushing for a third-round of stimulus checks, but it might be a while before we get them.
January 20, 2021
6 Reasons Why Your Second Stimulus Check Might Be Delayed
Coronavirus and Your Money

6 Reasons Why Your Second Stimulus Check Might Be Delayed

The IRS started delivering second-round payments in December. If you're still waiting for your money, here's why your second stimulus check could be l…
January 18, 2021

Recommended

The 7 Best Vanguard Index Funds for 2021
mutual funds

The 7 Best Vanguard Index Funds for 2021

Vanguard index funds are among the cheapest, easiest solutions for investors looking for diversified core holdings. Here are seven top options.
January 25, 2021
Kiplinger’s Mutual Fund Rankings, 2021
Kip 25

Kiplinger’s Mutual Fund Rankings, 2021

In a volatile year, the best portfolios had plenty of opportunity to shine.
January 23, 2021
12 Ways the Biden Stimulus Package Could Put (or Keep) Money in Your Pocket
Coronavirus and Your Money

12 Ways the Biden Stimulus Package Could Put (or Keep) Money in Your Pocket

President Biden's "American Rescue Plan" includes several proposals to assist people financially harmed by the pandemic.
January 20, 2021
The 11 Best Vanguard Funds for 2021
mutual funds

The 11 Best Vanguard Funds for 2021

It'd be easy to put together a full 2021 gameplan using nothing but a mix of the best Vanguard funds. Here are 11 that stand out for the year to come.
January 7, 2021